Insider Selling: Steven Shak Sells 13,348 Shares of Genomic Health Stock (GHDX)
Genomic Health (NASDAQ:GHDX) EVP Steven Shak unloaded 13,348 shares of Genomic Health stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $27.36, for a total value of $365,201.28. Following the completion of the sale, the executive vice president now directly owns 312,298 shares in the company, valued at approximately $8,544,473. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Genomic Health (NASDAQ:GHDX) traded up 0.22% during mid-day trading on Friday, hitting $27.76. The stock had a trading volume of 335,162 shares. Genomic Health has a one year low of $23.90 and a one year high of $37.24. The stock’s 50-day moving average is $26.70 and its 200-day moving average is $27.07. The company’s market cap is $875.2 million.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.11. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.04 million. During the same quarter last year, the company posted ($0.10) earnings per share. Genomic Health’s revenue was up 10.7% compared to the same quarter last year. Analysts expect that Genomic Health will post $-0.80 EPS for the current fiscal year.
Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Genomic Health in a research note on Monday. They now have a $27.00 price target on the stock, down previously from $30.00. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $27.50.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.